LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
24. März 2022 06:30 ET
|
LAVA Therapeutics N.V.
LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022LAVA-1207 Phase 1/2a trial in mCRPC on track to...
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
10. März 2022 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
07. März 2022 08:35 ET
|
LAVA Therapeutics N.V.
LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndromePharmacodynamic markers indicate increasing receptor occupancy with...
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
01. Februar 2022 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™...
Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
28. Januar 2022 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference
18. Januar 2022 08:30 ET
|
LAVA Therapeutics N.V.
The collective data indicate that LAVA’s approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and...
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20. Dezember 2021 10:06 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph...
LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20. Dezember 2021 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
15. November 2021 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on...
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
11. November 2021 10:08 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that...